Cashman John R
Human BioMolecular Research Institute, 5310 Eastgate Mall, San Diego, CA 92121, USA.
Biochem Biophys Res Commun. 2005 Dec 9;338(1):599-604. doi: 10.1016/j.bbrc.2005.08.009. Epub 2005 Aug 11.
This minireview summarizes information concerning the differences and similarities of the human flavin-containing- (FMO, E.C. 1.14.13.8) and the cytochrome P450-monooxygenases (CYP, E.C. 1.14.14.1). Human FMO oxygenates soft nucleophiles. CYP mainly catalyzes C-H abstraction but also oxidizes nitrogen- and sulfur-containing compounds. Both FMO and CYP generally convert lipophilic compounds into more hydrophilic metabolites. The mechanism by which each monooxygenase operates is quite distinct. Sometimes, CYP or FMO bioactivate chemicals to reactive metabolites but to date, drug toxicity thus far observed in the clinic is mainly the result of CYP-dependent oxidation. Both FMO and CYP possess genetic variability that may contribute to inter-individual variability observed for drug metabolism. In contrast to CYP, FMO is not induced or readily inhibited and potential adverse drug-drug interactions are minimized for drugs prominently metabolized by FMO. These properties may provide advantages in drug design, and by incorporating FMO detoxication pathways into drug candidates, more drug-like materials may emerge.
本综述总结了有关人类含黄素单加氧酶(FMO,酶编号1.14.13.8)和细胞色素P450单加氧酶(CYP,酶编号1.14.14.1)异同的信息。人类FMO使软亲核试剂发生氧化反应。CYP主要催化C-H键的提取,但也能氧化含氮和含硫化合物。FMO和CYP通常都将亲脂性化合物转化为更具亲水性的代谢产物。每种单加氧酶的作用机制截然不同。有时,CYP或FMO会将化学物质生物激活为活性代谢产物,但迄今为止,临床上观察到的药物毒性主要是CYP依赖性氧化的结果。FMO和CYP都具有遗传变异性,这可能导致药物代谢存在个体间差异。与CYP不同,FMO不会被诱导或轻易受到抑制,对于主要由FMO代谢的药物,潜在的不良药物相互作用会降至最低。这些特性可能在药物设计中具有优势,通过将FMO解毒途径纳入候选药物,可能会出现更多类似药物的物质